drugset / Trial / NCT02757040
Combination of Ibrutinib and As2O3 in the Treatment of CLL
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether the combination of As2O3 and ibrutinib is synergistic in chronic lymphocytic leukemia
Timeline
- Start
- 2016-12
- Primary completion
- 2017-12
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ibrutinib | Small molecule | — | — |
| Subject | arsenic trioxide | Small molecule | — | — |